CD52 and acute lymphoblastic leukemia: The world’s first therapeutic use of base-edited CAR T-cells for children with relapsed T-ALL was carried out by Chiesa and colleagues, who generated a base-edited CAR7 (BE-CAR7) with inactivation of three genes encoding CD52 and CD7 receptors and the β chain of the αβ T-cell receptor to evade lymphodepleting serotherapy, fratricidine, and GVHD, respectively.